Clinical Trials Logo
  1. Home
  2. Glaucoma
  3. NCT02085850
  4. Details
NCT02085850 Clinical Trial

Incidence and Progression of Glaucoma in the Tema Eye Survey Cohort

Glaucoma Clinical Trial

Official title:
Incidence and Progression of Glaucoma in the Tema Eye Survey Cohort

Clinical Trial Details — Status: Enrolling by invitation

Administrative data
NCT number NCT02085850
Other study ID # TCEC 066/13-14
Secondary ID
Status Enrolling by invitation
Phase N/A
First received March 11, 2014
Last updated March 11, 2014
Start date March 2014
Est. completion date March 2016

Study information
Verified date March 2014
Source Tema Christian Eye Center
Contact n/a
Is FDA regulated No
Health authority Ghana: The Food and Drug Authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Aim 1: To determine the incidence of glaucoma in Ghana in subjects previously found to be non-glaucomatous in the Tema Eye Survey.

Aim 2: To characterise the progression of glaucoma and the outcomes of subjects diagnosed with glaucoma in the Tema Eye Survey.

Recruitment information / eligibility
Status Enrolling by invitation
Enrollment 1375
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 40 Years and older
Eligibility Inclusion Criteria:

- glaucomatous and non-glaucomatous patients previously seen in the Tema Eye Survey who are selected and invited to participate

Exclusion Criteria:

- patients not previously seen in the Tema Eye Survey

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Locations
Country Name City State
Ghana Tema Christian Eye Center Tema

Sponsors (1)
Lead Sponsor Collaborator
Tema Christian Eye Center

Country where clinical trial is conducted

Ghana, 

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence of Glaucoma Day 0 No
Primary Progression of Glaucoma Day 0 No
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3